The present invention relates to pharmaceutical compositions comprising a cathepsin K inhibitor which are useful for treating such conditions as bone resorption, osteoporosis, arthritis, tumor metastases, Paget's disease, and other metabolic bone disorders characterized by increased bone resorption.